- en: <!--yml
  id: totrans-split-0
  prefs: []
  type: TYPE_NORMAL
  zh: <!--yml
- en: 'category: 未分类'
  id: totrans-split-1
  prefs: []
  type: TYPE_NORMAL
  zh: 类别：未分类
- en: 'date: 2024-05-27 13:10:01'
  id: totrans-split-2
  prefs: []
  type: TYPE_NORMAL
  zh: 日期：2024-05-27 13:10:01
- en: -->
  id: totrans-split-3
  prefs: []
  type: TYPE_NORMAL
  zh: -->
- en: Betty Chang
  id: totrans-split-4
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 作者：贝蒂·张
- en: 来源：[https://bettychang.xyz/advice-for-digital-health-founders/](https://bettychang.xyz/advice-for-digital-health-founders/)
  id: totrans-split-5
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
  zh: 来源：[https://bettychang.xyz/advice-for-digital-health-founders/](https://bettychang.xyz/advice-for-digital-health-founders/)
- en: 2023’s stacking up to be a bloodbath for early-stage digital health startups…
    and it’s only January. Digital health has always been challenging to build in
    — with lengthier sales cycles, higher implementation costs, and regulatory red
    tape all over. Tack on the pressure of rising interest rates making capital costly
    and startup valuations tank, investors are skittish. Funding into digital health
    startups in 2022 was [only half](https://rockhealth.com/insights/2022-year-end-digital-health-funding-lessons-at-the-end-of-a-funding-cycle/)
    of 2021’s.
  id: totrans-split-6
  prefs: []
  type: TYPE_NORMAL
  zh: 2023 年对于早期数字健康初创公司而言，堪称血腥一战……而现在才刚刚开始。长期以来，数字健康一直是一个具有挑战性的领域——销售周期较长，实施成本较高，各种监管限制层出不穷。加上利率上升增加资本成本和初创公司估值下跌的压力，投资者心存顾虑。2022
    年对数字健康初创公司的资金投入仅为 2021 年的一半。
- en: Yet, it’s a great time to build a digital health startup. Funding in 2022 marked
    the second highest year ever. Experienced investors are sticking around because
    the long-term opportunity is clear. And on top of that, the digital health gold
    rush over the past ten years has produced builders with earned industry knowledge.
    This resetting moment leaves us with more disciplined, profit-driven founders.
  id: totrans-split-7
  prefs: []
  type: TYPE_NORMAL
  zh: 然而，现在正是建设数字健康初创公司的好时机。2022 年的资金投入创下了有史以来第二高的年度。经验丰富的投资者依然坚守岗位，因为长期机会显而易见。此外，过去十年的数字健康热潮培养出了拥有行业经验的建设者。这一重置时刻使我们拥有更多具有纪律性和利润驱动的创始人。
- en: I’ve met with 100+ of these early-stage founders over the past year building
    both healthcare SaaS and tech-enabled care delivery services, to understand the
    challenges and opportunities across their companies. I’ve also gotten a front
    row seat of the successes and mistakes of my own healthcare infrastructure startup.
    I’m here to share with early-stage founders the common pitfalls I’ve seen *specific*
    to building in digital health — and advice on how to avoid them.
  id: totrans-split-8
  prefs: []
  type: TYPE_NORMAL
  zh: 我在过去的一年里与 100 多位早期创始人会面，他们分别致力于建设医疗 SaaS 和技术支持的护理服务，以了解他们公司所面临的挑战和机遇。我还亲身经历了我自己的医疗基础设施初创公司的成功与失败。我在这里与早期创始人分享我所见到的与数字健康建设相关的常见陷阱，并提供建议以避免这些问题。
- en: The goal is to help founders on the frontlines pushing healthcare innovations
    forward weather the storm over the next few years, so there are more winners that
    emerge and better outcomes delivered. I also hope this advice helps generalist
    investors better evaluate and win digital health deals, and support healthcare
    founders with empathy.
  id: totrans-split-9
  prefs: []
  type: TYPE_NORMAL
  zh: 目标是帮助那些在推动医疗创新前线的创始人们在接下来的几年里渡过难关，以便有更多的赢家涌现并带来更好的结果。我也希望这些建议能帮助通才投资者更好地评估和赢得数字健康交易，并以同情心支持医疗创始人。
- en: 'Advice covered:'
  id: totrans-split-10
  prefs: []
  type: TYPE_NORMAL
  zh: 建议内容：
- en: '[Surround yourself with a bilingual team who speaks tech and healthcare](#build-bilingual-teams)'
  id: totrans-split-11
  prefs:
  - PREF_OL
  type: TYPE_NORMAL
  zh: '[与技术和医疗领域双语团队合作](#build-bilingual-teams)'
- en: '[Start focused by building a wedge, not a platform](#be-a-tool)'
  id: totrans-split-12
  prefs:
  - PREF_OL
  type: TYPE_NORMAL
  zh: '[聚焦于构建楔子，而非平台](#be-a-tool)'
- en: '[Own the secret sauce in your digital health tech stack](#own-your-secret-sauce)'
  id: totrans-split-13
  prefs:
  - PREF_OL
  type: TYPE_NORMAL
  zh: '[拥有你的数字健康技术堆栈的核心秘密](#own-your-secret-sauce)'
- en: '[Sell into the whales of healthcare](#sell-into-the-whales)'
  id: totrans-split-14
  prefs:
  - PREF_OL
  type: TYPE_NORMAL
  zh: '[向医疗行业的大鱼销售](#sell-into-the-whales)'
- en: '[Manage your financial health obsessively, more so than non-healthcare peers](#manage-a-balanced-balance-sheet)'
  id: totrans-split-15
  prefs:
  - PREF_OL
  type: TYPE_NORMAL
  zh: '[要比非医疗同行更加重视财务健康管理](#manage-a-balanced-balance-sheet)'
- en: '[Deliver and track the right clinical outcomes](#obsess-over-the-right-clinical-outcomes)'
  id: totrans-split-16
  prefs:
  - PREF_OL
  type: TYPE_NORMAL
  zh: '[专注于提供和追踪正确的临床结果](#obsess-over-the-right-clinical-outcomes)'
- en: 1\. Surround yourself with a bilingual team who speaks tech and healthcare
  id: totrans-split-17
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 1\. 与懂技术和医疗的双语团队共事
- en: '*The pitfall: Founders who’ve never worked in healthcare, thinking they can
    build a successful healthcare company on their own.*'
  id: totrans-split-18
  prefs: []
  type: TYPE_NORMAL
  zh: '*陷阱：从未在医疗领域工作过的创始人，认为自己可以独立建立成功的医疗公司。*'
- en: 'In other industries, a compelling founder story may suffice as founder-market
    fit. Example: “I wear a lot of makeup, so am going to launch a new makeup line”
    says every celebrity makeup brand founder ever. But this doesn’t work in healthcare.
    Healthcare is still an exclusive and clubby industry, with a high learning curve
    to map out all the players and incentives.'
  id: totrans-split-19
  prefs: []
  type: TYPE_NORMAL
  zh: 在其他行业中，一个引人注目的创始人故事可能足够作为创始人市场适配。例如：“我化妆很多，所以我要推出一个新的化妆品系列”，这是每个名人化妆品品牌创始人说的话。但在医疗保健行业，这并不适用。医疗保健仍然是一个封闭和俱乐部式的行业，学习曲线高，需要制定所有参与者和激励措施。
- en: Having a bilingual team means having both technical and healthcare expertise.
    A common archetype you see in founders is the technologist-clinician duo. Being
    able to speak both clinical and technical language becomes an unfair advantage
    in making it easier to open doors to enterprise players and quickly building user-centered
    products that play well with practitioners’ and members’ entrenched workflows.
  id: totrans-split-20
  prefs: []
  type: TYPE_NORMAL
  zh: 拥有一个双语团队意味着同时拥有技术和医疗保健的专业知识。你在创始人中看到的一个常见原型是技术专家和临床医生的组合。能够同时掌握临床和技术语言，将成为在打开企业玩家大门和快速构建与从业者和会员深入合作的产品方面的不公平优势。
- en: As you hire your team, it’s especially important that this healthcare proficiency
    exists in your key product and sales hires. Your leadership teams needs to be
    able to translate patient and provider needs into roadmap, and build relationships
    with healthcare decision makers.
  id: totrans-split-21
  prefs: []
  type: TYPE_NORMAL
  zh: 当你雇佣团队时，特别重要的是你的关键产品和销售人员具备这种医疗保健的专业知识。你的领导团队需要能够将患者和提供者的需求转化为路线图，并与医疗保健决策者建立关系。
- en: If you don’t have the expertise on your founding team, supplementing with strong
    clinical advisors or strategic healthcare investors can be the next best thing.
  id: totrans-split-22
  prefs: []
  type: TYPE_NORMAL
  zh: 如果你的创始团队缺乏专业知识，那么补充强大的临床顾问或战略性医疗保健投资者可能是下一个最好的选择。
- en: '*The pitfall: Founders who start out by building an “all-in-one” digital health
    platform serving tons of different customer segments.*'
  id: totrans-split-23
  prefs: []
  type: TYPE_NORMAL
  zh: '*陷阱在于：创始人从构建“一体化”数字健康平台服务大量不同客户群体开始。*'
- en: 'For a time, I trialed the tagline, “Shopify for digital health” at my startup.
    It didn’t stick. The analogy of “Shopify” conjures up the image of a breadthy
    platform that you can build any patient engagement solution on top of. What I
    forgot was that Shopify in their early days had a clear value proposition they
    could point to in their product: helping e-commerce owners track orders and automate
    inventory automatically. They were a tool, not a platform.'
  id: totrans-split-24
  prefs: []
  type: TYPE_NORMAL
  zh: 曾经有一段时间，我在我的创业公司试用过“数字健康的Shopify”这个口号。但并没有留下深刻印象。将“Shopify”的类比引入，给人的印象是一个广泛的平台，你可以在其上构建任何患者参与解决方案。我忘记的是，在早期，Shopify有一个明确的价值主张，他们可以指向他们的产品：帮助电子商务所有者跟踪订单并自动管理库存。他们是一个工具，而不是一个平台。
- en: Instead of focusing on breadth, it’s smarter to build depth in the early days.
    The natural evolution of winners like Shopify are tool → platform → ecosystem.
    Be a wedge by doing one thing very well that solves a big pain point for customers.
    If your ambition is to build the “Shopify for digital health,” maybe wedge in
    by solving the [scheduling conundrum](https://www.healthtechstack.io/p/the-scheduling-conundrum?s=w)
    first. You’ll have a clear value proposition, more repeatable go-to-market motions,
    and differentiation of yourself in markets with growing numbers of competitors.
    This drives acquisition in your ICP, and customer value on your P&L.
  id: totrans-split-25
  prefs: []
  type: TYPE_NORMAL
  zh: 与其关注广度，早期建设深度更为明智。像Shopify这样的赢家的自然演变是工具 → 平台 → 生态系统。通过做一件事情做得非常好来成为一个楔子，解决客户的一个重大痛点。如果你的雄心是建立“数字健康的Shopify”，也许首先通过解决
    [排班难题](https://www.healthtechstack.io/p/the-scheduling-conundrum?s=w) 来切入。你将拥有一个明确的价值主张，更多可重复的市场推广动作，并在竞争对手日益增多的市场中区别于众。
- en: '**The key is that while you’re building a wedge, you should already have a
    vision, and ideally, multiple paths mapped for becoming a platform.** You should
    test hypotheses with your early customers in order to decide which paths will
    catapult you into becoming the winner of a market with large TAM. Expansion can
    take two flavors: how many new customers you can capture, and/or how much more
    ARPU you can capture.'
  id: totrans-split-26
  prefs: []
  type: TYPE_NORMAL
  zh: '**关键在于，在你构建一个楔子的同时，你应该已经有一个愿景，并且理想情况下，已经为成为平台制定了多条路径。** 你应该与早期客户测试假设，以决定哪些路径将推动你成为一个市场上大规模TAM的赢家。扩展可以采用两种方式：你能吸引多少新客户，和/或者你能提高多少ARPU。'
- en: 3\. Own the secret sauce in your digital health tech stack
  id: totrans-split-27
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 拥有数字健康技术堆栈中的秘密武器
- en: '*The pitfall: Founders who take venture dollars to build a tech company, but
    don’t build a tech moat and end up becoming a services company.*'
  id: totrans-split-28
  prefs: []
  type: TYPE_NORMAL
- en: Healthcare is a services industry with thin margins; [33%+ of hospitals](https://www.aha.org/costsofcaring)
    are operating on negative margins. The vision of tech-enabled care delivery is
    that the “tech” can lower COGS, increase revenue, and drive better margins; and
    this can produce venture-sized returns. Yet, there’s this inevitable pull in healthcare
    towards becoming services heavy, and for founders to eschew building their own
    tech in favor of speed to market.
  id: totrans-split-29
  prefs: []
  type: TYPE_NORMAL
- en: 'For a tech-enabled service, you avoid this trap by building and owning your
    secret sauce. A good exercise is to map out your product specs. Go down your feature
    set and ask yourself: Is it core to your clinical model? Does it differentiate
    you from competitors? Does it create future value for your enterprise strategy?
    If all three are checked, then it’s your secret sauce to build. Everything else,
    you can buy. Let’s take the example of a tech-enabled care navigation company;
    they’ll likely buy an off-the-shelf EHR and build the risk-scoring technology
    to power intelligent navigation.'
  id: totrans-split-30
  prefs: []
  type: TYPE_NORMAL
- en: What founders often forget is the long-term value created of owning your secret
    sauce from the start. As you grow, you aren’t dependent on external vendors (product
    limitations, changing pricing, vendor death), avoid switching costs, and can shore
    up your product IP and moat.
  id: totrans-split-31
  prefs: []
  type: TYPE_NORMAL
- en: 'A general rule of thumb to know if you’re on the right track:'
  id: totrans-split-32
  prefs: []
  type: TYPE_NORMAL
- en: 'On vendor death, as more and more “digital health tech stack” vendors have
    been spinning up with tempting promises to save companies time, money and compliance
    headaches, you should understand the risk of becoming reliant on a startup vendor
    who faces the same market pressures as you do. Always do your diligence on your
    vendor’s business, including asking for their runway ([see #5](#manage-a-balanced-balance-sheet)).'
  id: totrans-split-33
  prefs: []
  type: TYPE_NORMAL
- en: 'Meanwhile, for healthcare SaaS founders, be mindful of your implementation
    process. You don’t want to become a consulting services shop building systems
    integrators, doing custom work, and racking up high implementation costs for each
    customer. The goal is to be self-serve which oftentimes comes with being a tool,
    not a platform ([see #2](#be-a-tool)).'
  id: totrans-split-34
  prefs: []
  type: TYPE_NORMAL
- en: 4\. Sell into the whales of healthcare
  id: totrans-split-35
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
- en: '*The pitfall: Founders who see early success with small fish, with no plans
    to sell into whales.*'
  id: totrans-split-36
  prefs: []
  type: TYPE_NORMAL
- en: On the journey to product-market fit, founders are looking for quick and early
    signs of traction. For a tech-enabled service company, this means selling direct-to-consumer;
    and for a healthcare SaaS company, to independent practitioners, SMBs and other
    digital health startups. The trouble with these early successes is that it doesn’t
    scale, as you’ll ultimately run into high CAC, low ACV, and high churn.
  id: totrans-split-37
  prefs: []
  type: TYPE_NORMAL
- en: 'To achieve usage at scale, you need to have a plan of how you’re going to win
    enterprise from the start. [Derick En’Wezoh](https://www.linkedin.com/in/derickenwezoh)
    from Susa Ventures said it to be best: You’ve got to sell into the “whales” of
    healthcare — health plans, hospital systems, provider groups, and let’s include
    biopharma and employers in there too for good measure.'
  id: totrans-split-38
  prefs: []
  type: TYPE_NORMAL
  zh: 要实现规模化使用，您需要从一开始就制定一个赢得企业市场的计划。[Derick En’Wezoh](https://www.linkedin.com/in/derickenwezoh)
    来自 Susa Ventures 说得最好：您必须卖给医疗保健的“大鱼” — 包括健康计划、医院系统、服务提供者群体，还有生物制药和雇主，这样才算完整。
- en: These relationships take lengthy sales cycles to close — closing a hospital
    system averages 12 to 18 months to navigate their operational budget cycles (closing
    health plans take even longer!), identify an internal champion, put together a
    compelling ROI use case, and navigate bureaucratic procurement processes. Which
    is why you need to plan for your GTM upmarket earlier than later. The minute you
    see repeatable usage patterns among a core customer profile, you should begin
    your motions into enterprise.
  id: totrans-split-39
  prefs: []
  type: TYPE_NORMAL
  zh: 这些关系需要漫长的销售周期来结束 — 关闭一个医院系统通常需要12到18个月来处理他们的运营预算周期（关闭健康计划需要更长时间！），找到内部冠军，提出一个具有说服力的投资回报案例，并导航官僚主义采购流程。这就是为什么您需要尽早规划您的上市市场策略。一旦您看到核心客户群体中出现可重复使用的模式，就应开始向企业市场迈进。
- en: Another relevant pitfall I see here is founders thinking their enterprise strategy
    is completely separate from their DTC or SMB starting point. It’s true that SMB
    and enterprise sales are different motions and require different GTM teams. But
    **founders should be able to identify needs that are common to both small fish
    and whales so early traction can be laddered up into building a compelling ROI
    use case for enterprise.** For example, if you’re planning on doing VBC contracts
    with payers, you have to make sure your gathering the right evidence in your DTC
    channels. If you want to sell into big employers with a B2C2B strategy, it probably
    makes sense to focus your customer acquisition in regions where they have lots
    of employees.
  id: totrans-split-40
  prefs: []
  type: TYPE_NORMAL
  zh: 另一个相关的陷阱是，创始人认为他们的企业策略与他们的直接到消费者或小型企业起点完全不同。的确，中小企业和企业销售是不同的运动，需要不同的市场团队。但**创始人应该能够识别早期对小鱼和大鱼都通用的需求，这样早期的进展就可以升级到为企业建立一个具有说服力的投资回报案例**。例如，如果您计划与支付者签订VBC合同，您必须确保在直接到消费者渠道中收集到正确的证据。如果您想通过B2C2B战略向大雇主销售，可能需要集中您的客户获取工作在他们雇员众多的地区进行。
- en: Two resources I recommend here are [a16z’s B2C2B playbook](https://a16z.com/2021/12/01/b2c2b-in-digital-health-a-founders-playbook/),
    and Rock Health’s old but still highly relevant [guide on streamlining enterprise
    sales](https://rockhealth.com/insights/streamlining-enterprise-sales-in-digital-health/).
  id: totrans-split-41
  prefs: []
  type: TYPE_NORMAL
  zh: 我在这里推荐的两个资源是[a16z的B2C2B playbook](https://a16z.com/2021/12/01/b2c2b-in-digital-health-a-founders-playbook/)，以及Rock
    Health的老但仍然高度相关的[企业销售简化指南](https://rockhealth.com/insights/streamlining-enterprise-sales-in-digital-health/)。
- en: 5\. Manage your financial health obsessively, more so than non-healthcare peers
  id: totrans-split-42
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 5\. 您需要比非医疗行业的同行更加过分地管理您的财务健康
- en: '*The pitfall: Founders pushing growth at all costs, just to find themselves
    at the end of the line with zero cash in the bank.*'
  id: totrans-split-43
  prefs: []
  type: TYPE_NORMAL
  zh: '*陷阱：创始人不惜一切代价推动增长，最终发现银行账户一文不名。*'
- en: This is true for every founder, but I argue that healthcare founders need to
    manage their balance sheets even more closely. You must have a solid business
    model that bends the traditional P&L of care (remember those razor-thin margins?),
    either by making it less costly to provide care or by improving outcomes without
    making care more expensive. And in finding the right balance on the growth vs.
    profitability spectrum, err towards improving margins in these market conditions.
    Healthcare is a long game, which means being the one left standing at the end
    can be a competitive advantage in itself.
  id: totrans-split-44
  prefs: []
  type: TYPE_NORMAL
  zh: 这对每个创始人都适用，但我认为医疗创始人需要更加密切地管理他们的资产负债表。您必须有一个稳固的商业模式，可以通过降低提供护理的成本或者在不增加护理费用的情况下改善结果来弯曲传统的损益表（还记得那些微薄的利润率吗？）。在发展与盈利之间找到合适的平衡时，应当偏向于在这些市场条件下提高利润率。医疗是一场长期的游戏，这意味着最后留下来的人可能本身就具有竞争优势。
- en: 'There are some unique levers that are worth revisiting:'
  id: totrans-split-45
  prefs: []
  type: TYPE_NORMAL
  zh: 还有一些值得重新审视的独特杠杆：
- en: Firstly, sales cycles in healthcare are lengthier. You know that closing an
    enterprise customer could take 18+ months, so you should plan for at least two
    to three years of runway. [Daisy Wolf](https://www.linkedin.com/in/daisydwolf/)
    at a16z recommends founders go into investor conversations from a position of
    strength by having at least 12 months of runway. Running out of cash in healthcare
    doesn’t just impact employees, customers and investors; but more detrimentally,
    the human lives under care too.
  id: totrans-split-46
  prefs: []
  type: TYPE_NORMAL
  zh: 首先，医疗保健领域的销售周期较长。你知道，要关闭一个企业客户可能需要18个月以上的时间，所以你应该为至少两到三年的资金消耗做好计划。[Daisy Wolf](https://www.linkedin.com/in/daisydwolf/)
    在a16z建议创始人们在投资者谈判中保持优势地位，至少要有12个月的资金消耗能力。在医疗保健领域资金不足不仅会影响员工、客户和投资者，更严重的是受护理的人类生命。
- en: Secondly, COGS are generally higher, especially as you get up and running. For
    healthcare SaaS, this means implementation and support costs. For tech-enabled
    services, expect better gross margins over time (e.g., from 25% to 60%+) as you
    leverage tech to improve provider efficiencies. Be patient early on and expect
    lower gross margins than the generalized benchmarks that are published online.
  id: totrans-split-47
  prefs: []
  type: TYPE_NORMAL
  zh: 其次，成本价格（COGS）通常更高，特别是在初期运营时。对于医疗保健SaaS来说，这意味着实施和支持成本。对于技术支持的服务，随着你利用技术提高提供者效率，预期的毛利润将会有所提高（例如从25%增加到60%以上）。在初期要有耐心，预期的毛利润可能低于在线发布的一般基准。
- en: While this may ring alarm bells of “Why am I building (or investing) in healthcare,
    anyways?,” the big upside is there’s a much larger TAM to capture and higher YOY
    growth. Where the average TAM of a cloud SaaS business is $10B+, the average TAM
    of a tech-enabled healthcare service is 14x that.
  id: totrans-split-48
  prefs: []
  type: TYPE_NORMAL
  zh: 尽管这可能引起“我为什么要在医疗保健领域建立（或投资）公司？”的警觉，但巨大的上升空间在于有更大的市场可供占有，并且年年增长率更高。云端SaaS业务的平均市场容量（TAM）为100亿美元，而技术支持的医疗服务业务的平均TAM则是其14倍。
- en: Look to healthcare-specific benchmarks like [Bessemer’s Benchmarks for growing
    health tech businesses](https://www.bvp.com/atlas/benchmarks-for-growing-health-tech-businesses#3-Gross-profit-is-your-North-Star)
    to see how your costs and sales compare.
  id: totrans-split-49
  prefs: []
  type: TYPE_NORMAL
  zh: 参考医疗保健特定的基准，如[Bessemer对增长中的健康科技企业的基准](https://www.bvp.com/atlas/benchmarks-for-growing-health-tech-businesses#3-Gross-profit-is-your-North-Star)，以了解你的成本和销售如何相比。
- en: 6\. Deliver and track the right clinical outcomes
  id: totrans-split-50
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 6\. 提供并跟踪正确的临床结果
- en: '*The pitfall: Founders reciting ARR, EBITDA, LTV:CAC, ARPU, TAM… with no mention
    of clinical outcomes delivered.*'
  id: totrans-split-51
  prefs: []
  type: TYPE_NORMAL
  zh: '*陷阱：创始人们只重复提及ARR、EBITDA、LTV:CAC、ARPU、TAM等财务成果，却没有提到实现的临床结果。*'
- en: I sat in 75+ calls with investors when my startup was raising our seed round.
    It surprised me how often investors dug in on financial outcomes, and completely
    glossed over clinical outcomes. On the other side of the table, I’ve noticed founders
    making clinical claims splashed on their market site and ads, yet under the hood
    have [little clinical robustness](https://rockhealth.com/insights/assessing-the-clinical-robustness-of-digital-health-startups/).
    While financial outcomes are not always tied to clinical outcomes and vice versa,
    a successful digital health startup must be able to demonstrate both.
  id: totrans-split-52
  prefs: []
  type: TYPE_NORMAL
  zh: 在筹集我们的种子轮资金时，我参加了75+次与投资者的通话。让我惊讶的是，投资者多么频繁地深入研究财务结果，而完全忽视了临床结果。另一方面，我注意到，一些创始人在市场网站和广告上宣称具有临床效果，但实际上在内部却缺乏[足够的临床有效性](https://rockhealth.com/insights/assessing-the-clinical-robustness-of-digital-health-startups/)。虽然财务结果不总是与临床结果直接相关，反之亦然，但一家成功的数字健康初创公司必须能够展示两者兼顾。
- en: Founders should be obsessed with delivering and tracking the right clinical
    outcomes. What’s “right” will vary based on your model. A good exercise is to
    write down the measures that matter most to all the different stakeholders of
    your solution, including patients, practitioners, current buyers and future enterprise
    buyers. Understanding what measures overlap between all your stakeholders will
    help prioritize and align goals and incentives. Tracking them longitudinally will
    help you identify how to improve the quality and effectiveness of your services.
  id: totrans-split-53
  prefs: []
  type: TYPE_NORMAL
  zh: 创始人们应该专注于提供和跟踪正确的临床结果。什么是“正确的”将根据你的模型而异。一个好的方法是写下对你解决方案的所有不同利益相关者最重要的衡量标准，包括患者、从业者、现有买家和未来的企业买家。理解所有利益相关者之间的重叠衡量标准将有助于优先考虑和对齐目标和激励措施。长期跟踪它们将帮助你识别如何提高服务的质量和有效性。
- en: When you’re starting out, your dataset may be limited, but you can point to
    compelling qualitative customer testimonials or references. Over time, you’ll
    rely on more and more quantitative data like readmission, mortality, safety of
    care, and NPS scores. And getting FDA clearance or approval on your device and
    therapeutics, running clinical trials, and publishing results in academic journals
    can establish your clinical IP and moat.
  id: totrans-split-54
  prefs: []
  type: TYPE_NORMAL
  zh: 当您刚开始时，您的数据集可能有限，但您可以指向引人注目的定性客户见证或参考。随着时间的推移，您将依赖越来越多的定量数据，如再入院率、死亡率、护理安全性和NPS得分。并且获得FDA的清算或设备和治疗的批准，进行临床试验，并在学术期刊上发表结果可以建立您的临床知识产权和护城河。
- en: 'Playing the long game, all these outcomes will be packaged into a compelling
    ROI use case to convince risk-adverse enterprise customers into making a purchasing
    decision ([see #4](%28#sell-into-the-whales%29). For example, that your virtual
    pre- and post-ops care navigator for the surgery department can decrease no-show
    rates, improve timeliness of care for patients, and increase revenue.'
  id: totrans-split-55
  prefs: []
  type: TYPE_NORMAL
  zh: 玩长远的游戏，所有这些结果将被打包成一个引人注目的投资回报用例，以说服风险厌恶的企业客户做出购买决策（[见＃4](%28#sell-into-the-whales%29)）。例如，您的虚拟术前和术后护理导航器可以降低未按时出诊率，改善患者护理的及时性，并增加收入。
- en: Ultimately, make the case for how clinical outcomes are also good for your customer’s
    financial outcomes; for example, in improving engagement, helping you to upsell,
    and reducing member churn.
  id: totrans-split-56
  prefs: []
  type: TYPE_NORMAL
  zh: 最终，证明临床结果对客户的财务结果也是有益的；例如，在提高参与度、帮助您提升销售和减少会员流失方面。
- en: '* * *'
  id: totrans-split-57
  prefs: []
  type: TYPE_NORMAL
  zh: '* * *'
- en: The best time to build in digital health
  id: totrans-split-58
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 现在是构建数字健康的最佳时机。
- en: If I had five cents for every time I’ve heard someone say, “This is the best
    time to build,” I’d have a dollar. (Actually, [Yoni Rechtman](https://www.linkedin.com/in/yrechtman/)
    from Slow Ventures made me aware that he [published an article titled exactly
    this](https://99d.substack.com/p/the-best-time-to-build), so it’s $1.05 now.)
    I’m apologizing in advance that you have to hear it again.
  id: totrans-split-59
  prefs: []
  type: TYPE_NORMAL
  zh: 如果我听到有人说，“现在是构建的最佳时机”，我可以赚到五分钱。事实上，[Yoni Rechtman](https://www.linkedin.com/in/yrechtman/)来自Slow
    Ventures让我意识到他 [发表了一篇题为这样的文章](https://99d.substack.com/p/the-best-time-to-build)，所以现在是$1.05。我提前道歉，您又要听到这句话了。
- en: I believe this is the best time to build in digital health, and that the biggest
    digital health unicorns are going to come from this downturn — because they’ll
    be healthy, profitable, disciplined businesses.
  id: totrans-split-60
  prefs: []
  type: TYPE_NORMAL
  zh: 我相信现在是构建数字健康的最佳时机，最大的数字健康独角兽将在这一衰退中诞生 — 因为它们将是健康的、盈利的、有纪律的企业。
- en: I want to support early-stage founders who’re in the trenches building these
    unicorns. If you have other common pitfalls and advice to share, I’d love to hear
    and collate them as additional resources to founders. Reach out via [email](/cdn-cgi/l/email-protection#d2b0a6a6abb1babcb592b5bfb3bbbefcb1bdbf)
    or [Twitter](https://www.twitter.com/thebettychang).
  id: totrans-split-61
  prefs: []
  type: TYPE_NORMAL
  zh: 我希望支持那些正在一线建设这些独角兽的初创创始人。如果您有其他常见的陷阱和建议要分享，我很乐意听取并整理它们作为创始人的额外资源。通过[电子邮件](/cdn-cgi/l/email-protection#d2b0a6a6abb1babcb592b5bfb3bbbefcb1bdbf)或[Twitter](https://www.twitter.com/thebettychang)联系我。
- en: '*Tons of gratitude to [Yoni Rechtman](https://www.linkedin.com/in/yrechtman/),
    [Sean Day](https://www.linkedin.com/in/seantday/), and [Daisy Wolf](https://www.linkedin.com/in/daisydwolf/)
    for the feedback and notes on this article.*'
  id: totrans-split-62
  prefs: []
  type: TYPE_NORMAL
  zh: '*感谢[Yoni Rechtman](https://www.linkedin.com/in/yrechtman/)、[Sean Day](https://www.linkedin.com/in/seantday/)和[Daisy
    Wolf](https://www.linkedin.com/in/daisydwolf/)对本文的反馈和意见。*'
